TELLOMAK: T-CELL LYMPHOMA ANTI-KIR3DL2 THERAPY: AN OPEN LABEL, MULTI-COHORT, MULTI-CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T-CELL LYMPHOMA
| Autor: | Hélène Sicard, Pierluigi Porcu, P. L. Zinzani, Youn H. Kim, H. A Azim, Martine Bagot |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Phases of clinical research Hematology General Medicine medicine.disease KIR3DL2 Internal medicine Cohort medicine T-cell lymphoma Center (algebra and category theory) In patient Open label business |
| Zdroj: | Hematological Oncology. 37:72-73 |
| ISSN: | 0278-0232 |
| DOI: | 10.1002/hon.40_2629 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text